Prostamax — a short peptide bioregulator studied for prostate tissue support and cellular aging.
Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) belonging to the family of short peptide bioregulators developed to influence tissue-specific cellular processes. It was designed with prostate tissue in mind, fitting into a broader research tradition that pairs short peptides with the organs they appear to support — cardiogen for heart tissue, bronchogen for lung, prostamax for prostate.
What draws researchers to Prostamax is its apparent ability to act at the level of chromatin — the packaged form of DNA inside the cell nucleus. As cells age, chromatin tends to become more tightly compressed, silencing genes that were once active. Prostamax appears to gently loosen this packaging, potentially restoring access to genes that aging had quieted. This places it in an interesting category of peptides that may work not by adding signals to a cell, but by reopening the cell's own genetic toolkit.
1 vendor carries Prostamax.
Compare prices →The most distinctive line of Prostamax research focuses on what happens inside the nuclei of aged cells. In lymphocytes from individuals aged 75 to 88, treatment with Prostamax was shown to activate ribosomal genes, loosen densely packed chromatin fibrils, and reverse the age-related silencing of facultative chromatin — the regions of DNA that get progressively shut down as cells grow older (4). Prostamax also produced decondensation of structural chromatin around the centromere of chromosome 1, a region typically locked tight throughout life.
A follow-up study in cells from individuals aged 75 to 86 found that Prostamax increased sister chromatid exchange frequency from about 5.9 to 12 events per cell and roughly doubled the count of active ribosomal gene markers (Ag-positive NORs), while reducing the bulky pericentromeric heterochromatin segments on chromosomes 1 and 9 (1). Together, these findings suggest Prostamax may release genes that aging had repressed, potentially restoring some of the transcriptional flexibility characteristic of younger cells.
Biophysical work using differential scanning calorimetry — a technique that measures how chromatin unfolds when heated — supports this picture. Prostamax shifted chromatin denaturation patterns in human lymphocytes in ways consistent with partial relaxation of the 30-nanometer chromatin fiber and subtle changes in nucleosomal packing (3). The peptide appears to be acting directly on how DNA is folded, not just on which genes are turned on.
Prostamax was developed within a framework that pairs each short peptide with a target tissue, and its target is the prostate gland. In organotypic tissue culture work — where small explants of organ tissue are kept alive outside the body and exposed to candidate compounds — Prostamax at a concentration of 0.05 ng/ml stimulated growth and reparative activity in prostatic explants compared to untreated controls (2). The effect held across tissue from both young and aged subjects, suggesting Prostamax may help prostate tissue maintain its regenerative capacity regardless of starting age.
This tissue-specificity is a recurring theme in short peptide research: cardiogen acts preferentially on heart explants, bronchogen on lung explants, and Prostamax on prostate explants, even when tested side by side under identical conditions (2). The mechanism is thought to involve the peptide entering cells and influencing gene expression in tissue-appropriate ways, consistent with the chromatin-level effects observed in lymphocyte studies.
A separate microcalorimetric study examined how Prostamax interacts with environmental stressors at the chromatin level. Researchers exposed lymphocyte cultures from aging individuals to copper and cadmium ions — metals known to alter chromatin packaging — alone and together with Prostamax (5). Copper ions caused additional condensation of heterochromatin (further tightening already compacted DNA), while cadmium ions caused decondensation along with partial denaturation of chromatin structure.
The study positions Prostamax as a bioregulator being studied alongside known chromatin-modulating agents, helping clarify how short peptides may fit into the broader picture of how cells respond to environmental and age-related pressures on their genetic material (5). It also reinforces that Prostamax's primary action seems to take place at the level of how DNA is organized inside the nucleus, rather than through classical receptor signaling.
Reported side effects in the published Prostamax research are minimal — across the cytogenetic, biophysical, and tissue culture studies available, no significant adverse effects have been described (1, 2, 3, 4). Long-term safety in humans has not been formally characterized, as the necessary clinical trials have not been completed.
The body of Prostamax evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far. Most findings derive from cytogenetic studies on lymphocytes from elderly donors and tissue explant cultures, which provide mechanistic insight but do not establish clinical outcomes. Prostamax does not appear on the World Anti-Doping Agency's prohibited list at this time.
All information on this site is for research and educational purposes only. The compounds discussed are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.